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Imaging readouts as biomarkers or surrogate
parameters for the assessment of therapeutic
interventions
Abstract Surrogate markers and
biomarkers based on imaging readouts
providing predictive information on
clinical outcome are of increasing
importance in the preclinical and
clinical evaluation of novel therapies.
They are primarily used in studies
designed to establish evidence that the
therapeutic principle is valid in a
representative patient population or in
an individual. A critical step in the
development of (imaging) surrogates
is validation: correlation with
established clinical endpoints must be
demonstrated. Biomarkers must not
fulfill such stringent validation
criteria; however, they should provide
insight into mechanistic aspects of
the therapeutic intervention (proof-
of-mechanism) or document therapy
efficacy with prognostic quality with
regard to the long-term clinical
outcome (proof of concept). Currently
used imaging biomarkers provide
structural, physiological and metabol-
ic information. Novel imaging
approaches annotate structure with
molecular signatures that are tightly
linked to the pathophysiology or to the
therapeutic principle. These cellular
and molecular imaging methods yield
information on drug biodistribution,
receptor expression and occupancy,
and/or intra- and intercellular signal-
ing. The design of novel target-spe-
cific imaging probes is closely related
to the development of the therapeutic
agents and should be considered early
in the discovery phase. Significant
technical and regulatory hurdles have
to be overcome to foster the use
of imaging biomarkers for clinical
drug evaluation.
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Biomarker/surrogate markers
The term surrogate, from the Latin surrogatum, means
substitute/substitution. In the biomedical context a surrogate
endpoint substitutes for an established clinical endpoint, i.e., it
is expected to predict clinical benefit based on epidemiologic,
pathophysiologic or other scientific evidence [1]. Narrowing
down even further to the evaluation of novel therapies,
surrogates are parameters that predict the effect of treatment in
clinical studies. Such readouts might be of a structural,
physiological, metabolic, cellular or molecular nature.
A critical aspect when considering the use of surrogates is
validation: the parameters must show a tight correlation
with classical clinical endpoints requiring large-scale multi-
center clinical trials. It is obvious that validation studies for
surrogate marker development are both time consuming
and expensive, and may involve large patient populations.
Biomarkers are not validated to the extent of a surrogate.
According to a United States Food and Drug Administra-
tion (FDA) definition, a “biomarker is a characteristic that is
objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or
pharmacological responses to a therapeutic intervention”
[2, 3]. Biomarkers are typically developed on the basis of
mechanistic considerations. Consider a drug aimed at
inhibiting a target enzyme. Demonstration that the drug is
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effectively inhibiting the enzyme would be regarded as
proof of the pharmacological principle. However, it is
obvious that enzyme inhibition may not necessarily predict
beneficial outcome for patients. There is a reasonable
likelihood that normalization of a biomarker (or of a bio-
marker profile) might translate into an improved clinical
status of the patient; but there is the complementary
probability that the predictionmight be wrong. In contrast, a
surrogate would inevitably predict the therapeutic outcome.
Nevertheless, biomarkers are highly attractive for both
preclinical and clinical drug evaluations, not necessarily for
clinical phase III trials, but rather for small-scale clinical
studies aiming at demonstrating that a therapeutic concept is
also valid in humans (proof-of-concept studies), critical
information in the decision making on further development.
Biomarkers are used as indicators of pharmacodynamic
endpoints in patients, to assess translatability from animal
studies to clinical studies correlating preclinical and clinical
data, to establish the optimal dosing regimen and to stratify
patient populations, i.e., to identify subgroups of patients
that are most likely to respond to treatment. Pharmacody-
namic measures reflect the effects of an intervention (e.g., a
drug treatment) on the organism, i.e., structural, physiolog-
ical or metabolic changes imposed by treatment. In contrast,
pharmacokinetics (PK) analyzes how the organism handles
a drug, i.e., how it is absorbed, distributed, metabolized and
excreted by the body.
Biomarkers in order to be predictive early markers of
therapy response have to be linked to the pathophysiology
of the disease process. Moreover, the readout should be (1)
on the ‘critical path’ leading to pathological transformations
and (2) downstream of the therapeutic intervention.
Otherwise, it will not be useful as an indicator of clinical
outcome (Fig. 1). A biomarker not associated to the
dominant mechanism leading to disease might well indicate
therapy response, however, would not predict clinical
outcome. An example is inhibition of acetylcholine esterase
(AChE) as symptomatic treatment in Alzheimer’s disease
(AD), which can be monitored using suitable radio-labeled
enzyme inhibitors. However, AChE inhibition is not disease
modifying; the readout will not predict the long-term
clinical outcome.
The Critical Path Initiative of the FDA aims at
accelerating the drug development process, which for a
newmolecular entity currently takes more than 10 years and
costs about 800 million US dollars. The initiative should
ensure that ‘basic scientific discoveries translate more
rapidly into new and better medical treatment by creating
new tools to find answers about how the safety and
effectiveness of new medical products can be demonstrated
in faster time frames, with more certainty, at lower cost and
with better information’ [2]. In March 2006 the FDA
released the Critical Path Opportunity List, which com-
prises six key areas; of relevance in the context of this article
is the section on new evaluation tools - biomarker and
disease models. The agency is convinced that drug
development programs will benefit from the availability
of biomarkers, including imaging biomarkers, imaging
methods being considered key enabling technologies. The
FDA sees a critical role of biomarkers and surrogate
endpoints in providing evidence (1) for validation of a
therapeutic target, (2) for the elucidation of mechanism of
action of drug candidates, (3) for demonstrating proof-of-
principle of a therapeutic intervention, (4) for stratification
patient populations, and (5) for the evaluation of therapy
response or eventual side effects [2].
Imaging biomarkers
There are a number of advantages of gathering information
to document the disease course or evaluate therapeutic
interventions using imaging methods:
1. ‘Seeing is believing’: Capturing biological processes
or consequences thereof as imaging data sets provides
evidence of high documentary value that allow an
‘objective’ assessment of the patient status.
Fig. 1 (Imaging) biomarkers should probe disease-relevant path-
ways. Moreover, the readout should be downstream of the
therapeutic intervention (indicated by the syringe) in order to
predict clinical outcome (top). For an intervention downstream of
the checkpoint, treatment effects will not be captured (2nd row). In
case of multiple mechanisms involved in the pathophysiological
process, the therapy effect will be likely missed if the biomarker
measurement probes a different pathway than that of the interven-
tion (3rd row). In the last case (bottom) the biomarker will capture
the drug effect; however, it is not the dominant mechanism leading
to disease and may therefore not predict clinical outcome
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2. Imaging methods are versatile, i.e., techniques can be
used to probe a wide range of pathological conditions.
Combining multiple imaging readouts might provide
biomarker profiles that are of higher diagnostic
relevance than individual markers.
3. Non-invasiveness enables longitudinal studies in
individuals: The current status can thus be related to
baseline values: Measuring relative changes to a
reference state accounts for part of the inter-individual
variability and thus enhances statistical power.
4. Imaging results are inherently quantitative: Structural
consequences of a disease process and treatment
efficacy can be assessed via morphometric measures
such as the volume of a structure. When probing tissue
function using exogenous tracers, densitometric anal-
ysis is commonly used to estimate local tracer
concentrations in tissue or tissue compartments, a
prerequisite for deriving quantitative physiological
parameters. Obtaining biologically relevant quantita-
tive information from an imaging data set is by no
means straightforward; major methodological devel-
opments are required.
Imaging biomarkers in clinical drug trials: structural,
functional and molecular readouts in disorders
of the central nervous system (CNS)
Imaging biomarkers are currently being developed for a
wide range of human pathologies. It is beyond the scope of
this article to comprehensively cover all active areas of
research. In the following section we focus on structural
and functional imaging readouts used to characterize stroke
and neuro-degeneration of the Alzheimer type (AD).
(1) Stroke/focal cerebral ischemia: Multiple aspects of
the pathophysiological cascade of focal cerebral ischemia
can be monitored in great detail, using, e.g., MRI, from the
initial vascular occlusion to post-acute events such as the
infiltration of immune competent cells [4]. While many of
these imaging procedures are primarily of experimental
interest, some have matured to clinically established tools.
For assessment of therapy response in stroke, the following
imaging readouts are considered relevant:
Exclusion of cerebral hemorrhage for stratification of
patients It is widely accepted that CT and MRI can both be
used to differentiate ischemic stroke from cerebral hem-
orrhage, a critical distinction when considering thrombo-
lytic therapy using recombinant tissue plasminogen
activator (rt-PA), which is currently the only agent
approved by the FDA for the treatment of acute stroke.
Large randomized trials that had used CT to exclude brain
hemorrhage showed benefit from treatment with rt-PA
when administered within 3 h following the insult [5].
Thus, structural imaging biomarkers are routinely used for
patient stratification.
Perfusion-diffusion mismatch to predict outcome A critical
parameter for predicting therapy response in focal cerebral
ischemia is the identification of “tissues at risk” in case of
sustained hypoperfusion. CT- or MRI-based perfusion
imaging approaches allow rapid identification of areas with
compromized perfusion [6]. A second early readout of
pathology is the formation of a cytotoxic edema reflecting a
redistribution of tissue water between the intra- and extra-
cellular compartments due to failure of membrane pumps.
These pumps are membrane-spanning proteins that are
critical for maintaining concentration gradients across cellu-
lar membranes and thus the polarization of the membrane.
Membrane pumps transport ions in and out of cells against
concentration gradients, a process requiring energy. Energy
failure leads to the breakdown of ion homeostasis, inducing a
change in osmolarity and thus to a redistribution of tissue
water. This results in a decrease of the apparent diffusion
coefficient (ADC) of water. ADC values are sensitive early,
yet are not specific indicators of an ischemic insult [7]. The
early ischemia markers ADC and CBF are potentially pre-
dictive with regard to the final infarct volume: a significant
perfusion-diffusion mismatch, a marker for the ischemic
penumbra with the ‘perfusion lesion’ being larger than that
derived from ADC maps, is a strong predictor of lesion
growth [8]. Such information may be translated into risk
maps [9] describing the likelihood for a specific brain area to
become infarcted in the absence of treatment. Deviation from
this ‘outcome’ might be considered the result of a therapy.
Using such imaging readouts, a patient might be used as his/
her own control when assessing treatment response.
Structural versus functional readouts of therapeutic
efficacy Cytoprotective therapy using a variety of pharma-
cological strategies has been demonstrated to reduce the
volume of infarction in animal models of focal cerebral
ischemia, infarct volume (and location) being considered a
biomarker of outcome [10]. The demonstration that regions
spared from becoming infarcted are functional would be
convincing evidence that infarct volume is a valid efficacy
biomarker of anti-ischemic therapy. Studies in MCA
occluded rats that were treated with a calcium antagonist
confirmed the hypothesis only in part: recovery of the
function in cortical areas spared from becoming infarcted
has been observed; however, only a fraction of the animals
showed a fully recovered fMRI response, while the
remaining animals of the drug-treated group did not recover
at all. All animals displayed a similar reduction of the infarct
volume as compared to placebo-treated animals; in
particular the somato-sensory cortex has been spared from
becoming necrotic in all drug-treated animals [11, 12]. The
results imply that structural integrity is a necessary, yet not
sufficient criterion for functional integrity. Correspond-
ingly, the biomarker ‘infarct volume’ tends to overestimate
drug efficacy as far as functional (clinical) recovery is
concerned. Whether these findings can be translated to
clinical stroke care remains to be shown.
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(2) Neurodegenerative diseases/Alzheimer dementia:
With an aging population neuro-degenerative diseases
have become a major health issue. There is an extensive
effort worldwide to develop effective therapies against
diseases such as Alzheimer dementia (AD). A major issue
with regard to accelerating clinical drug development is the
slow pace of disease progression rendering the evaluation of
novel therapies tedious, emphasizing the need for biomar-
kers for AD that yield early information treatment response.
Many imaging techniques have been used to analyze
structural, functional or metabolic alteration in patients
suffering from AD or from mild cognitive impairment,
which is associated with a high risk to develop AD. A
number of candidate imaging biomarkers have been
proposed. It is beyond the scope of this article to review
all of them (see, e.g., [13]). We will focus on well-
documented examples.
Assessing gross-morphological changes of the brain/
atrophy Neuronal loss in AD is accompanied by both
general and focal brain atrophy that can be accurately
assessed by volumetric analysis of structural MRI data [13]
(Fig. 2). It has been shown that the rate of cerebral atrophy,
i.e., volume loss per annum, is significantly higher in AD
patients as compared to age-matched healthy controls [14,
15]. Hence, measurement of the rate of cerebral atrophy
might be considered an indicator of disease severity and
thus be used to assess potential therapeutic interventions
that might slow down progression or even cause arrest of
brain shrinkage. Issues with this biomarker are the high
demands on accuracy of both data acquisition and analysis
(image co-registration, criteria used for tissue segmenta-
tion) in order to pick up small volume changes reliably and
the potentially long duration required for a study (typically
several months to more than 1 year for a proof-of-concept
study). In addition, atrophy is a rather non-specific marker
of AD. Similarly, non-specific functional imaging readouts
in dementia include markers of brain function such as
cerebral blood flow (CBF) and cerebral glucose utilization,
although careful analysis of spatial patterns of abnormal-
ities might be more disease specific [16].
Early clinical manifestations of AD include loss of
short-term memory and cognitive impairment. A number
of fMRI studies have been carried out in patients suffering
from mild cognitive impairment and AD using a variety of
stimulation paradigms (sensory input, cognitive tasks,
working memory tasks). Significant region-specific altera-
tions in fMRI signals have been reported; while these
changes vary significantly in the different studies, they
were consistent in displaying alterations when compared
to age-matched controls [17]. Similar experiments have
been carried out in transgenic mouse models of AD or of
cerebral amyloidosis. The cortical and thalamic fMRI
responses to pharmacological and sensory stimulation are
Fig. 2 Brain atrophy as struc-
tural biomarker in AD. The rate
of brain volume reduction is
significantly higher in patients
suffering from AD as compared
to age-matched healthy persons.
Images show a cross-section
through the brain of an age-
matched healthy volunteer (left)
and an AD patient (right)
obtained from MRI. The brain
volume is extracted by segmen-
tation based on intensity thresh-
olds. The cross-sectional area
(and correspondingly the
volume) is significantly smaller
in the patient. The accuracy of
morphometric analyses critically
depends on the initial image
quality, in particular the
contrast-to-noise ratio, and the
performance of the registration
and segmentation processing
tools. (Images: courtesy
of Nitsch R, Division of
Psychiatric Research, University
of Zürich, Switzerland)
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significantly reduced in APP23 mice over-expressing the
human amyloid precursor protein (APP) as compared to
age-matched controls. The functional impairment was
observed before any atrophy could be measured [18].
Readouts of cholinergic transmission AD is characterized
by a progressive dysfunction of the cholinergic system and
current therapies aim at increasing the availability of
acetylcholine (ACh) for synaptic transmission by inhibiting
acetylcholine esterase (AChE) [19]. In longitudinal studies,
progressive loss of cholinergic activity could be demon-
strated using AChE-binding PET ligands [20]. The same
tracer has been used to demonstrate pharmacological
efficacy: administration of AChE inhibitors has been
shown to displace the PET ligands from AchE [21].
Alternatively, the cholinergic system can be probed by
analyzing post-synaptic receptors: studies with 11C-labeled
nicotine demonstrated up-regulation of nicotinic ACh
receptors by AChE inhibitors [22]. Functional conse-
quences of AChE inhibition have been documented in
AD patients following treatment with the AChE inhibitor
rivastigmin: Drug treatment led to a significant increase in
the fMRI response in multiple brain regions in a task-
dependent manner [23]. These results can be related to data
obtained in the rat: administration of rivastigmin prompted
a region-specific hemodynamic response (increase cerebral
blood volume), which was dependent on the dose of the
drug (Fig. 3; [24]). Obviously, these molecular and
functional imaging biomarkers provide valuable mecha-
nistic information, i.e., clinical proof-of-concept that AChE
inhibition infact enhances cholinergic transmission in AD
patients. However, they do not unambiguously predict
whether inhibiting ACh degradation will translate into an
improved clinical outcome (see Fig. 1).
Amyloid plaque load as disease indicator The histo-
pathological hallmarks of AD are deposits consisting of
β-amyloid peptides (amyloid or Aβ plaques), and neuro-
fibrillary tangles composed of hyper-phophorylated tau-
protein in brain parenchyma. Quantitative assessment of the
parenchymal plaque load would therefore constitute an
attractive biomarker for characterizing AD. Attempts to
visualize plaques using high-resolution MRI by exploiting
the intrinsic contrast of plaques to the surrounding paren-
chyma both in tissue specimens from humans [25] and of
transgenic mice [26] have shown that translation of this
Fig. 3 Cholinergic activation in
rat brain. Oral administration of
the AChE inhibitor rivastigmin
leads to region-specific
increases of local CBV. Images
(left) show baseline CBV and
CBV changes following dosing
with 8 mg/kg rivastigmin. Bar
graphs shows regional CBV
changes in caudate putamen,
thalamus and parietal cortex
with a dose dependency in the
caudate and parietal cortex
(adapted from [24])
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approach to a clinical setting is unrealistic due to
prohibitively long measurement times as a result of the
high demands on spatial resolution. An alternative approach
is the selective detection of plaque-related signals by
administering Aβ -specific tracer molecules. For example,
administration of one such PET tracer to AD patients
revealed significant increases in cortical tracer binding with
an inverse correlation between amyloid tracer binding and
regional glucose metabolism as assessed using [18F]-fluoro
deoxyglucose (FDG) as PET label [27]. Similar data have
been obtained in genetically engineered mouse models of
AD using plaque-binding fluorescent dyes [28]; yet the
latter approach is of limited value for clinical applications
due to insufficient light penetration through the human
skull, but nevertheless constitutes an attractive technique
for preclinical evaluation of AD treatments. From a clinical
perspective, plaque-selective PET ligands are the most
promising imaging agents for visualization and quantifica-
tion of the plaque load in humans [29]. However, it has been
reported that the correlation between Aβ plaque load and
clinical status in AD patients is rather weak, i.e., significant
plaque deposition was observed in completely asymptom-
atic elderly people [30]. To what extent quantitative
assessment of plaque load constitutes a reliable biomarker
of therapy efficacy in AD is currently unclear.
Physiological and molecular markers in cancer
Morphological and physiological manifestations of disease
and of therapeutic interventions must be preceded by
aberrations at the cellular and/or molecular level. Hence,
visualization and quantification of these parameters should
increase the sensitivity and specificity of diagnosis and
provide earlier evidence of therapy efficacy than the
classical imaging readouts. Molecular imaging, which aims
at annotating anatomical structures with molecular infor-
mation, is currently developed at a rapid pace and beyond
doubt will have a major impact on patient management. In
this section we will focus on molecular biomarkers for
cancer (see Table 1).
Several hallmarks are characteristic of neoplastic tissues:
excessive proliferation, increased metabolic activity, for-
mation of new blood vessels, dysregulation of cellular
homeostasis and the tendency to form colonies distant from
the primary tumor site. In addition, tumor cells may express
specific receptors that might be utilized for tumor targeting.
(1) Targeting general tumor hallmarks: The classic
readout when assessing tumor proliferation and treatment
efficacy is tumor volume using structural imaging methods
such as CT, MRI or ultrasound. Although clinically well
established, structural readouts are recognized to be poor
indicators of response. This is undesirable from several
perspectives: from a drug developer’s perspective an early
readout is desired in order to optimize the treatment
strategy and to reduce development cost. More importantly,
Table 1 Potential imaging biomarkers for oncology
Tumor hallmark Mechanisms Imaging biomarker Development status
Angiogenesis/vascularity Vascular permeability Dynamic contrast-enhanced MRI (DCE-MRI)
using low molecular weight contrast agents
Evaluation/deployment
Vascular permeability/blood volume DCE-MRI using macro-molecular
contrast agents
Development/evaluation
Metabolism Glucose utilization (glucose
transporter and hexokinase
activity)
[18F]-2-fluoro-2-deoxyglucose
PET (FDG-PET)
Deployment
Proliferation Membrane turnover MR spectroscopy (MRS):
phosphorylcholine signal
Evaluation
[18F]-fluorocholine PET (FCh-PET) Development/evaluation
DNA synthesis [18F]-fluoro-thymidine PET
(FLT-PET)
Evaluation/deployment
Apoptosis Apoptotic cell body formation MRI: Apparent water
diffusion coeffient
Evaluation
Externalized phosphatidyl-
serine
99mTc-Annexin-5A Evaluation/development
as diagnostic
Cell surface receptor
over-expression
Somatostatin receptor
(SSTR) binding
111In-DTPA-D-Phe-octreotide Deployment/diagnostic
product (Octreoscan)
Estrogen receptor binding [18F]-fluoro-estradiol Identification/development
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patients may be exposed to potentially ineffective therapy
for prolonged periods of time.
Structural growth requires the synthesis of molecular
building blocks of cells. DNA, protein and membrane
phospholipid synthesis rates are therefore potential in-
dicators of proliferation. Imaging approaches, and in
particular PET methods, have been developed to probe
each of these processes. PET-based approaches use radio-
labeled precursor molecules such as labeled thymidine
analogues [31], amino acids [32] or choline [33, 34].
Proliferation marker Thymidine kinase 1 (TK) is a key
enzyme in DNA synthesis. It phosphorylates thymidine, a
prerequisite for DNA incorporation. TK activity can be
monitored by administration of radio-labeled substrates.
The thymidine analogue [18F]-3′-fluoro-3′-deoxythymi-
dine (FLT) is a substrate for TK, which has been
thoroughly evaluated as a potential indicator of DNA
synthesis. FLT is taken up by cells and phosphorylated by
TK, leading to intracellular trapping [35]. Tumor levels of
radio-labeled nucleotides (thymidine analogues) then
reflect DNA synthesis and, correspondingly, cell prolifer-
ation [36, 37]. Clinically, this approach is highly attractive,
in particular for tissues with high intrinsic glucose
utilization, where the established [18F]-2-fluoro-2-deoxy-
glucose (FDG) method (see below) might be compromised
by poor signal-to-background ratios. Clinical validation of
FLT as a proliferation marker is ongoing.
Rapid cell proliferation is associated with high protein
synthesis rates and high demands on re-supply of amino
acids. There is experimental evidence that amino acid
transport is up-regulated in experimental tumors. Labeled
amino acid precursors (such as [18F]-fluorotyrosine) might
be used to monitor protein synthesis. However, preclinical
and clinical results up to now using fluorinated amino
acids show that tissue uptake rates are dominated by slow
amino acid transport across the cell membrane rather than
actual protein synthesis rates [38].
Increased proliferation rates are also associated with
increased rates of membranes synthesis, and substrates
required for membrane synthesis constitute another po-
tential proliferation markers. In fact, magnetic resonance
spectroscopy (MRS) studies of tumors revealed some
characteristic common spectral features: (i) elevated
signals of endogenous phosphomonoester (PME) and -
diester (PDE), (ii) elevated intensity of the ‘choline’ signal,
and (iii) early decreases in the PME signal as predictor of
therapy response [39]. These data point to the role of PME
and PDE in membrane biosynthesis and degradation
pathways. In vivo MRS is currently evaluated by several
groups for its potential as a prognostic tool and as a
potential biomarker for treatment efficacy. Alternatively,
PET using radio-labeled choline derivatives, for example
[11C]-choline, first evaluated for imaging of brain tumors,
could be used to assess lipid membrane turnover [40].
There is evidence that for tumors located in tissues with
high intrinsic glucose utilization (e.g., brain), measure-
ment of choline accumulation yields higher tumor-to-
background values as compared to FDG PET imaging.
Metabolic marker/glucose utilization Measurement of
glucose utilization rates via FDG PET has evolved as a
sensitive diagnostic tool for the characterization of primary
tumors and for the detection of metastases. FDG is taken
up by cells via the glucose transporter and phosphorylated
by hexokinase to yield FDG-6-phosphate (FDG-6P). This
metabolite is not further processed through the glycolytic
chain (due to the lack of a hydroxyl group at the 2-
position). Because of the phosphate group added, FDG-6P
is charged and trapped in the cell. Hence, the trapping of
Fig. 4 Effect of tyrosine kinase
inhibitor imatinib mesylate in a
patient with a bowel GIST
(short arrow) suffering from
multiple liver and peritoneal
metastases (long arrow). 18F-
FDG PET and CT studies were
carried out prior and at various
days following drug treatment.
Within 8 days after the start of
the imatinib treatment, 18F-FDG
uptake in neoplastic tissue was
completely abolished, while a
significant reduction of the liver
tumor burden could be observed
after 24 weeks only (adapted
from [41], reproduced with
permission)
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FDG-6P by the cells reflects glucose transporter and
hexokinase activity and the PET activity becomes a marker
for the glycolytic activity of the tissue of interest. There is
convincing evidence in several clinical drug trials that
changes in glycolytic rate precede effects on the tumor
volume. For example, in patients suffering from gastro-
intestinal stromal tumors treated with imatinib, an inhibitor
of cKIT tyrosine kinase (and of BCR-ABL, an oncogenic
tyrosine kinase associated with chronic myeloid leuke-
mia), glucose utilization was significantly reduced within
24 h after treatment onset, while there was no effect on
tumor volume for several weeks (Fig. 4) [41], indicating
that the glucose utilization rate predicts therapy response.
Angiogenesis marker Neo-vascularization is a critical
factor promoting tumor growth. A driving factor of
angiogenesis is hypoxia, which leads to the expression
of angiogeneic factors. Tissue, and in particular tumor
hypoxia, can be imaged using PET or MRI approaches
[42]. The alternative and more widely used approach to
study tumor neovasculature uses so-called dynamic con-
trast-enhanced (DCE) MRI methods, which exploits the
fact that newly formed immature vessels are characterized
by increased vascular permeability. DCE-MRI measures
the leakage of low molecular weight contrast agents such
as GdDTPA (Magnevist) or GdDOTA (Dotarem) into the
extracellular space. The method is currently being
evaluated as a biomarker for evaluating anti-angiogenic
therapy efficacy [43–45].
The vascular endothelial growth factor (VEGF, also
known as vascular permeability factor) is an angiogenic
factor induced by most solid tumors. Inhibition of VEGF
receptor signaling should be reflected by decreased vascular
permeability and potentially also reduced tumor blood
volume. This has been demonstrated in rodent tumor
models [46, 47]. In both an orthotopic kidney tumor model
and B16 melanoma model in mice, the VEGF-R tyrosine
kinase inhibitor vatalanib (PTK787) significantly reduced
vascular leakage in B16 melanoma lymph node metastases,
the decrease occurring within 48 h after onset of therapy.
Clinical studies in patients with liver metastases yielded
corresponding results indicating that, in fact, vascular
permeability measures may serve as a biomarker of anti-
VEGF drug efficacy [48]. Vascular permeability assessment
using DCE-MRI is meanwhile a widely evaluated biomar-
ker and has become a gold standard for assessing anti-
angiogenic response. The method has been used for
translational studies with a number of compounds (vatalanib
[46–48], combretastatin [49], ZD6126 [50, 51]).
While DCE-MRI is widely used for early clinical
evaluation of anti-angiogenic drugs, the approach suffers
from shortcomings due to the use of low molecular weight
contrast agents: the tracers leak into the interstitial space
also in mature vessels, which compromises the dynamic
range of the measurement, and display high diffusive
mobility. The local concentrations of the contrast agents
and, hence, the signal enhancement at the tumor site are
governed by perfusion rates, vascular leakage and inter-
stitial diffusion. Using DCE-MRI in combination with
macromolecular contrast agents alleviates these limitations
(Fig. 5): perfusion and extravasation could be more easily
separated due to different time scales of the processes, and
the contribution of diffusion would be largely negligible
[52]. Unfortunately, no macromolecular contrast agents
are currently approved for clinical use in this indication.
Apoptosis marker Programmed cell death is an essential
process for cell homeostasis, and down-regulation of
apoptosis is associated with excessive cellular proliferation
associated with malignancies. Induction of apoptosis is an
attractive therapy concept in oncology and many cyto-
statics display a pro-apoptotic component. Several imag-
ing strategies for visualizing activation of the apoptotic
pathway are conceivable.
Cells undergoing apoptosis redistribute aminophospho-
lipids to the outer leaflet of the cell membrane [53]. These
extracellular aminophospholipids, primarily phosphatidyl-
serine, are recognized by phagocytotic cells prompting a
signal for cell removal [54]. Externalized phosphatidylser-
ine moieties are recognized by annexin-5A [55], which
binds to its target with high affinity and specificity.
Specific imaging probes have been designed by coupling
reporter groups such as radioligands (99mTc-chelates) to
annexin-5A [56]. Labeled annexin-5A has been used to
demonstrate therapy-induced apoptosis in cancer patients
[57] and in animal models. For example, chemotherapy
using cyclophosphamide in a murine tumor model led to
induction of apoptosis within hours after drug administra-
tion as reflected by increased annexin binding [56, 58].
Radiolabeled annexin-5A is currently in clinical develop-
ment as a potential radiodiagnostic.
Indirect imaging approaches, sensitive to microstructur-
al or metabolic changes associated with apoptosis, have
also been proposed. Apoptosis-inducing therapy results in
increases in water ADC in a rat glioma model early after
treatment onset prior to any changes in tumor volume [59].
The effect was attributed to increases in the extracellular
volume due to the formation of apoptotic bodies. Studies
in glioma patients also have revealed early increases in
ADC following chemotherapy, indicating that ADC values
might serve as potential biomarkers to assess pro-apoptotic
treatment response [60].
Metastasis formation Detection of metastases is of high
diagnostic and prognostic relevance for cancer patients.
Today, the gold standard imaging approach for detection
of metastasis is FDG-PET, which is characterized by high
sensitivity, but poor spatial resolution. The detection limit
is currently of the order of 5-mm tumor diameter [61]. An
advantage of PET is that the whole body can be efficiently
screened for metastasis. Limitations include radiation
exposure to patients.
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MRI has emerged as an attractive alternative for
detection of lymph node metastases. The approach uses
the fact that particulate matter and pathogens that are
recognized by the immune system are cleared from
circulation by the cells of the monocyte phagocytotic
system (MPS). This has be exploited by developing long
circulating nanoparticles containing a core of iron oxide
(small and ultra-small particles of iron oxide: SPIO and
USPIO, or mono-crystalline iron oxide nanoparticles:
MION), which due to their super-paramagnetic properties
have a strong effect on the contrast inMRI (shortening of T2
and T2* relaxation times) [62]. While healthy lymph node
tissue shows massive uptake of USPIO/MION, metastatic
tissue does not. There is compelling preclinical and clinical
evidence of the improved diagnostic sensitivity and spec-
ificity of the approach using USPIO/MION for detection of
lymph node metastases [63, 64]; approval of the approach
by the regulatory authorities is expected soon.
Protease activity marker A characteristic feature of tumors
is excessive secretion of proteases, which among other
effects, degrades the extracellular matrix and enables
tumor infiltration into healthy tissue. Identifying areas of
increased protease activity would be attractive with regard
to tumor detection and to assess the efficacy of protease
inhibitors. An elegant approach uses activatable or ‘smart’
near-infrared fluorescent probes [65, 66] that will only
generate a signal upon interaction with their target. Such a
probe has been used to assess the efficacy of the matrix
metalloprotease (MMP) inhibitor prinomastat in a murine
tumor model, providing direct proof-of-mechanism of the
therapeutic concept, protease inhibition [67]. For clinical
application, this approach is limited due to light scattering
in biological tissue, confining penetration of NIR light to a
few centimeters requiring the development of endoscopic
procedures (e.g., coloscopy for imaging colorectal tumors).
The usefulness of a specific protease imaging probe is
tightly linked to the validity of the respective protease as
drug target. MMP inhibitors are aimed at inhibiting
cellular penetration of the basement membrane and,
therefore, tissue infiltration by malignant cells. Yet,
MMPs have been found to also exert host-protective
functions such as suppression of angiogenesis or inacti-
vation of chemokines. As a therapeutic strategy MMP
inhibition has failed in clinical trials [68]. Currently, it is
not clear whether the trials as such failed (trial design, side
effects, inappropriate dosing) or whether MMP inhibitors
failed as a drug class. Imaging biomarkers might help to
resolve this issue, providing relevant mechanistic informa-
tion both in animals and eventually in the patient [68].
Fig. 5 DCE-MRI (a) and simulation results (b) for uptake of low
molecular weight (left) and macromolecular contrast agent (right) in
subcutaneously implanted mammary tumor in nude mice. Tissue
model comprises three compartments: healthy tissue (h), proliferating
tumor (pt) and necrotic tumor core (nc), which in contrast to the other
two compartments is not vascularized. Tracer transport processes
considered in the simulation are perfusion, diffusive transport and
convective transport. Note different patterns of contrast enhancement
reflecting local tissue concentrations of the two contrast agents
observed 20 min after administration. Simulation results indicate a
significant contribution of molecular diffusion for the low molecular
weight tracer (experimental MRI data: courtesy of Allegrini P,
Novartis Institute of Biomedical Research Basel; Simulation results:
Grimm HP, Kuttler A, Rausch M, Rudin M, unpublished)
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(2) Targeted tumor probes: Suitable targets for imaging
as well as for therapeutic intervention comprise peptide
receptors that are frequently over-expressed in specific
neoplastic tissue. Targets include the somatostatin recep-
tors in neuroendocrine tumors, gastrin-releasing peptide
receptors in prostate and breast cancer and neuropeptide Y
receptors in breast cancer [69]. Several corresponding
peptide ligands have been radio-labeled and are being
evaluated as potential imaging probes.
Membrane-bound somatostatin receptors (SSTRs) are
highly expressed in neuroendocrine tumors and as such
represent attractive targets for a tumor-specific imaging
probe. Their endogenous ligand is somatostatin, a neuro-
peptide with a short plasma half life. A metabolically
stabilized somatostatin analogue, octreotide, has been used
as a targeting template to which various reporter groups
have been coupled. 111In-DTPA-D-Phe-octreotide has been
developed to the clinically approved probe 111In-pentetreo-
tide (Octroscan) for SPECT imaging. Administration of
such ligands leads to highly specific enrichment at the
tumor site both in patients suffering from neuro-endocrine
tumors [70] and in animal models thereof [71]. There are
several other radiopeptides that are currently being
evaluated as tumor-specific imaging agents such as bom-
besin or cholecystokinin, e.g., in prostate cancer [69].
Inhibition of intracellular signaling via the estrogen
receptor (ER) pathway is an established strategy in the
therapy of breast cancer [72]. This can be achieved by
various strategies, e.g., using ER inhibitors such as
tamoxifen that compete with the endogenous receptor
ligand, by lowering the concentration of the endogenous
agonist (aromatase inhibitors) or by inducting ER degra-
dation [72]. Assessment of ER levels would be of high
value for diagnostics and in particular for development of
new therapies. Several agents are currently being evaluated
for PET ER imaging [73, 74]. For example, [18F]-fluoro-
estradiol (FES; [75]) shows great promise for assessing the
functional ER status in breast cancer patients by PET:
quantitative levels of FES uptake in primary tumors
correlate positively with the level of ER expression [76]
and allow the detection of metastatic lesions in patients
with ER-positive tumors [77, 78]. A recent study indicated
that quantitative FES PET imaging predicts the response to
endocrine treatment in breast cancer and may help guide
treatment selection [79]. While such results are certainly
encouraging, only multi-center studies designed with
adequate statistical power will demonstrate the value of
FES-PET for therapeutic decision making.
The Her-2/neu (c-erb B-2) tyrosine kinase receptor is
overexpressed in approximately 25% of human breast
cancers [80]; higher expression levels have been shown to
correlate with poor prognosis. Her-2/neu constitutes a
potential target for immunotherapeutic agents such as the
humanized monoclonal antibody trastumazab (Herceptin),
which has shown promising results in HER2/neu over-
expressing cancers [81]. A PET imaging probe has been
developed using a 68Ga-chelate as a reporter moiety [82].
Initial experiments were carried out using the full mono-
clonal antibody with covalently linked DOTA chelating
groups revealing excellent tumor targeting in murine tumor
xenografts; however, pharmacokinetic (PK) properties of
this probe turned out unfavorably. A probe based on
antibody fragments showed improved PK characteristics at
the expense of a slightly compromised binding affinity.
This probe has been used to assess the response to
treatment with an inhibitor of heat shock protein 90
(HSP90), which was shown to effectively and potently
reduce levels of Her2/neu expression within hours after
therapy onset [82], an important feature of a potential
biomarker. HSP are stress-induced proteins that are up-
regulated in many tumors. HSP are molecular chaperons
assisting proper protein folding and stabilizing unfolded
proteins, including oncogenic proteins expressed by
malignant cells; hence, inhibition of HSP by low molecular
weight ligands or antibodies is currently evaluated as
anticancer therapy and several of these drugs are in clinical
development [83].
Imaging biomarkers: some challenges
Imaging methods providing quantitative structural, func-
tional and more recently also cellular and molecular
information in a non-invasive manner have become valuable
tools for the evaluation of drug candidates. Imaging enables
longitudinal studies in an individual allowing the evaluation
Fig. 6 (Imaging) biomarker
development chain. Biomarkers
should be available for deploy-
ment when the drug enters clin-
ical trials, e.g., for clinical
proof-of-concept (POC) studies,
requiring timely initiation of the
biomarker development process.
Development to a surrogate
endpoint requires extensive va-
lidation studies comparing bio-
marker readouts with classically
accepted endpoints
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of therapy response with respect to a pre-treatment reference
state, which will benefit from a significant reduction of the
inter-individual variability. Furthermore, non-invasive diag-
nostic imaging will allow stratification of patient groups to
achieve homogeneous cohorts enhancing the statistical
power of a therapy evaluation study.
An important aspect in drug development is the timely
availability of biomarkers of therapeutic efficacy (Fig. 6).
This is relevant both for the drug developer and for the
patient. A considerable number of potential imaging
biomarkers are currently in preclinical or clinical evaluation
(see Table 1 listing potential biomarkers for assessment of
cancer treatment), and it is likely that several of those will
make a major impact on the development of future therapies.
Nevertheless, several issues have to be addressed by drug
developers, regulators and the imaging community to fully
exploit the potential of imaging biomarkers.
1. General versus specific biomarkers: Imaging biomar-
kers may reflect alterations of a general disease
hallmark as discussed above for tumors (proliferation,
metabolism, angiogenesis, apoptosis) or cerebral vas-
cular disease (lesion volume, perfusion, cell swelling,
metabolism), or alternatively reflect specific molecular
interactions at the level of a drug target. Imaging of
specific biomarkers is certainly highly attractive from a
mechanistic point of view, and the concept of
personalized therapy involving a diagnostics/therapeu-
tics pair has raised considerable interest recently.
However, the more target specific a biomarker is, the
higher the risks associated with its development as an
imaging tool. As soon as the target is not further
pursued by the therapy developer, the biomarker
becomes obsolete. Thus, development of imaging
biomarkers will focus-at least initially-on more general
readouts that are of relevance for a wide range of
diseases such as the markers of tumor hallmarks already
mentioned or markers of inflammation (e.g., antigens
expressed activated endothelium, infiltration of mono-
cytes and lymphocytes). Specific biomarkers will be
developed as diagnostics for ‘high value’ targets, such
as the examples already discussed in the cancer area
(e.g., Her-2/neu) or, e.g., a probe targeting monomeric
or aggregated Aβ peptide as a marker of AD, which
would be of relevance for large patient populations.
2. Validation studies: Validation of a surrogate requires
correlation with established clinical endpoints, e.g.,
survival in a cancer study, involving large-scale clinical
studies, in particular when targeting chronic diseases.
The surrogate in order to be acceptable for regulatory
authorities must reliably predict clinical outcome at the
level of the individual and when considering a
population. The prognostic value of the surrogate is
given by its dynamic range and its variability. The
dynamic range describes the sensitivity to the disease
process and the therapeutic intervention: how small a
change can be reliably detected? The ability to detect
small changes might translate in earlier readouts of
efficacy. Factors determining surrogate variability are
biological and methodological variation. From the point
of view of multicenter trials, standardization of the
measurement process (hardware, measurement proto-
cols and analysis procedures) becomes a critical issue.
Few imaging readouts have been developed to the
surrogate stage so far. For example, MRI outcome
measures have been shown to provide objective
evidence for the clinical endpoints in multiple sclerosis
(MS). Despite this, imaging readouts cannot be
considered fully validated surrogates of clinical out-
come in MS. While they capture the inflammatory
component of the disease, axonal loss leading to
progressive disability is not reflected. Nevertheless,
when considering therapeutic interventions that aim at
preventing relapses, new Gd-enhancing and T2 lesions
can be considered a surrogate outcome measure; these
MRI readouts qualify as the primary measure for
evaluating the anti-inflammatory treatment efficacy of
novel MS drugs [84, 85].
Response Evaluation Criteria In Solid Tumors (RE-
CIST) were modified in 2000 to objectively character-
ize the effect of treatment on tumor volume [86, 87].
Based on radiological (principally CT) readouts, anti-
tumor effects are classified into complete response,
partial response, no change and progressive disease.
This RECIST classification has become an integral part
of most clinical cancer therapy studies-however, they
are not surrogates replacing the clinical endpoint,
which is patient survival, but rather constitute
supportive evidence. There are instances of both
clinical benefit without tumor regression and tumor
regression without clinical benefit [86].
Biomarkers are not validated to the extent of surrogates.
More often they reflect mechanistic aspects of the
disease process or the therapeutic intervention or
provide (early) objective evidence that an individual is
responding to treatment. Criteria for the development of
biomarkers are mechanistic plausibility, availability of
methods and technologies, and translatability into the
clinics. Whether these readouts will predict clinical
outcome is not their primary purpose. For example,
measurement of vascular leakiness is a widely used
biomarker for evaluating anti-angiogenic therapy. DCE-
MRI provides early information about whether a patient
responds to the therapy-important information for the
drug developer. However, the readout will, in general,
not predict clinical outcome (tumor regression and
patient survival).
When developing an imaging biomarker for clinical
use, important aspects to consider are technical
feasibility (for example, the application of optical
imaging techniques in the clinics will be severely
impaired by limited tissue penetration of light),
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performance of clinical vs. preclinical instrumentation,
translatability of experimental protocols, accuracy and
reproducibility of the biomarker measurement, dynamic
range of the biomarker and the availability of contrast-
enhancing agents for clinical use (see, e.g., discussion
about low molecular weight and macromolecular con-
trast agents for assessing vascular permeability).
3. Standardization: Avalidated (imaging) biomarker must
deliver quantitatively consistent results independent of
the observer, instrumentation or institution. This
requires standardization of the study design, acquisi-
tion protocols and data analysis procedures as clinical
studies are commonly designed as multi-center trials.
4. Biomarker profile instead of individual biomarkers: A
single biomarker cannot capture the complex aspects
of a disease such as cancer. This has, for example, been
demonstrated in clinical studies of colorectal cancers
evaluating the biomarker potential of both vascular
(perfusion, blood volume) and metabolic parameters
(glucose utilization) for the evaluation of therapy
effects. Treatment with the monoclonal antibody
bevacizumab significantly reduced readouts reflecting
vascularity as derived from perfusion CT, but did not
affect glucose utilization rates [88]. In contrast, a
decrease of the glucose utilization rate was highly
indicative for treatment response to imatinib in GIST
tumors [41]. The suitability of a biomarker to assess
therapy of malignant tumors depends on the tumor type
and the therapeutic principle; complementary informa-
tion provided by different biomarkers will enhance the
diagnostic/prognostic value.
Combination of the multiple imaging modalities will
allow comprehensive characterization of pathophysio-
logical processes and therapeutic interventions at the
receptor level by monitoring individual signaling
cascades, and finally via the morphological, physio-
logical and metabolic consequences of these molecular
events. For the drug developer multimodality imaging
should become an important instrument for under-
standing drug effects at the level of the whole
organism. The combination of multiple readouts results
in a biomarker profile, similar to proteomics and
metabonomics [89], enhancing the specificity and
sensitivity of diagnostic tools. Profiles might be
analyzed using statistical tools such as a generalized
linear model (GLM). This approach has been applied,
e.g., to generate risk maps from perfusion and ADC
data in patients suffering from stroke [9]. GLM-derived
information can be used to evaluate therapeutic
interventions by comparing what the model predicts
would happen to each voxel in the absence of therapy
with the actual outcome following treatment at the
level of individuals. Of course, this approach is not
limited to stroke studies, but constitutes a general
concept. A methodological limitation is the basic
assumption that parameters should be related in a linear
fashion, which is unlikely to be the case for a complex
biological system. More sophisticated non-linear
approaches are therefore required. Clinical parameters
such as age [90], general health status and genetic
factors are likely to affect outcome and might be
considered in more general statistical approaches. The
inclusion of both genotypic and phenotypic informa-
tion will thus become increasingly important factors in
predictive models [9, 90]. As stated in the context with
the Critical Path Initiative, ‘a multidimensional and
continuous model needs to replace the current single
dimension, binary model of clinical effect’ [3].
5. Improved tools for quantification: It is essential to
translate primary imaging data into biomedically
relevant quantitative information. Extraction of mor-
phometric information is, in general, straightforward
provided that there is high enough contrast-to-noise for
image segmentation. Accurate estimation of physiolog-
ical and molecular parameters is more difficult and
requires the development of tissue models of various
degrees of sophistication. As such models are currently
largely inadequate, imaging readouts are frequently
expressed by parameters derived from primary imaging
data sets, such as the area under the signal enhancement
curve during the first 90 s following tracer administra-
tion in DCE-MRI studies of tumors [44], or as relative
deviations of parameter values from the normal, healthy
state. This raises the principal question: how normal is
‘normal’? Is the reference region a valid control?
Furthermore, as already stated, biological systems are
not linear. Considering brain perfusion, there are
thresholds for cell function and cell survival; hence,
minimal changes in the blood flow to the tissue may
have dramatic consequences [91]. Clearly, improved
methods for modeling biological systems are required.
6. Regulatory issues: Currently, the development and
registration of a new diagnostic agent are comparable
to the development of a novel therapeutic, despite a
significant lower market potential. As a result, there are
only a very limited number of diagnostic imaging
agents currently available for large-scale clinical usage.
For example, the manufacturer of ferumoxtran-10
(Combidex/Sinerem) submitted a marketing authoriza-
tion application (MAA) for the compound as a
functional molecular MRI imaging agent to aid in the
differentiation of normal from metastatic lymph nodes
to the European Medicines Agency (EMEA) only in
December 2006 [92]. The product had been refused by
the FDA for the same use in 2004 despite clear
evidence of efficacy. The overall development process
took more than 10 years, similar to that of a
therapeutic. Of course, not all imaging biomarkers
involve the development of novel diagnostics; never-
theless, in the context of the Critical Path Initiative, it
becomes obvious that the approval process for diag-
nostics tools has to be carefully analyzed, and the
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agencies seem willing to do so. A step in the right
direction is the so-called ‘microdosing concept’ [93],
which holds for tracers that are administered in sub-
pharmacological doses (at least two orders of magni-
tude lower than doses prompting a pharmacological
response). In this case, the requirement for application
of the tools in clinical studies would be only evaluation
for acute toxicological and safety effects of the tracer.
Both regulatory agencies, the EMEA [94] and the FDA
[95], support the concept as stated in their recent
position papers.
Conclusion
Imaging is increasingly being applied in the preclinical and
clinical evaluation of novel therapies. Being non-invasive,
imaging allows sample sizes to be reduced by comparing
outcome measures with pretreatment values (baseline),
which will allow reducing trial costs significantly. The
primary role of such studies is to establish proof-of-concept,
i.e., to demonstrate that the pharmacological principle is
valid in patients.
Current largely established imaging biomarkers are
based on structural (e.g., RECIST for tumors, infarct
volume for stroke, lesion load for MS) or physiological
readouts (e.g., DCE-MRI and glucose utilization rates for
tumors). However, it is clear that a next generation of
(molecular) imaging approaches will provide specific
mechanistic information tightly linked to the therapeutic
pharmacological principle, the design of novel molecular
imaging probes being closely related to the development of
the therapeutic agents (111In-pentetreotide and octreotide
are an example of such a pairing).
The FDA Critical Path Initiative [2], which aims at
modernization of the development process for medical
products, is also a milestone for the development and
deployment of biomarkers as tools for therapy evaluation.
Definitions for biomarkers, surrogate endpoint and clinical
outcome accepted by a regulatory authority set guidelines
for drug developers. As outlined above, imaging-based
biomarkers and surrogate endpoints may provide informa-
tion on critical aspects during therapy development such as
target validation or proof-of-concept of the therapeutic
principle. Nevertheless, there are few imaging biomarkers
and even fewer surrogates based on imaging readouts that
are currently accepted by the FDA as appropriate tools in
clinical trials. There are, however, a significant number of
candidates currently in the pipeline as illustrated for cancer
biomarkers (Table 1); some of them might soon become
available for clinical drug development.
Obviously there are of number of regulatory issues
associated with the use of biomarkers in drug development
that need to be resolved. As already pointed out, proper
validation is an expensive and time-consuming process.
Regulatory acceptance of biomarkers that do not fulfill
stringent validation criteria, but provide insight into
mechanistic aspects of the therapeutic intervention, with
documentation of biomarker usefulness in a disease-specific
manner would help advance the field [2, 3]. The main driver
of the process will be the pharmaceutical industry in
collaboration with academia and regulators. Development of
biomarkers, including imaging biomarkers, will become an
important new aspect in the development of a novel
therapeutic; these tools must be ready for deployment
when the clinical phase is entered (Fig. 6). Clear regulatory
criteria for the development and use of such markers as well
as guidelines for efficient co-development of therapeutic/
biomarker pairs are required [3].
Apart from being accepted as biomarkers or surrogate
endpoints by regulatory agencies, rapid readouts on
efficacy and mechanism will provide valuable information
for early ‘go/no-go’ decision making with regard to further
development of the drug/therapy as illustrated for treatment
of cancers with anti-angiogenic drugs [43–51] or tyrosine
kinase inhibitors [41]. Positive outcomes of proof-of-
concept studies provided confidence for the initiation of
large-scale phase III trials.
While the availability of imaging biomarkers during the
early clinical phases is highly attractive and clearly favors
an early embarking in marker development, potentially
during the lead optimization or profiling phase, this
strategy also carries substantial risk in view of the high
attrition rates involved in the drug development pipeline.
This becomes even more relevant when considering a
molecular biomarker that is tightly linked to the mechanism
of action of a therapeutic, i.e., a specific target. As this
target is dropped (e.g., because of lack of efficacy or
because of safety issues), the marker will most likely
become obsolete, while the indication as such might still be
of interest. Therefore, many of the markers that are
currently being evaluated reflect generic properties of
pathology. For cancer imaging probes for processes such as
proliferation, angiogenesis, metabolism and apoptosis are
being evaluated by many centers, while only few probes
targeting tumor-specific antigens (receptors) are being
considered (herceptin, octreotides). In contrast, for brain
imaging a number of target-specific PET ligands probing
various neurotransmitters systems have been described;
these tracers are attractive to characterize a large variety of
CNS disorders or effects of neuro-active compounds [96].
Imaging has become an established tool in pharmaceu-
tical research, in particular at the preclinical level during
lead optimization and profiling, where it is used for more
than 2 decades to characterize drug effects in animal
models of human disease [10]. Translation of these
methods into clinical studies, however, has been less
straightforward than anticipated; few biomarkers are
currently being used for clinical drug evaluations. There
are technical reasons accounting for this deficiency: the
clinical imaging toolset is more limited than that at the
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preclinical level, safety regulations are more stringent, and
contrast agents might not yet be approved for clinical use.
Clinical trials are in general designed as multi-center
studies raising issues regarding standardization of data
acquisition and analysis, which become even more
problematic in view of the rapidly evolving imaging
hardware, acquisition protocols, analysis tools and novel
contrast-enhancing principles. Also, lack of sufficient
evaluation/validation of imaging biomarkers has prevented
their use in early clinical studies. The major stakeholders,
i.e., the regulatory authorities, drug development industry
and academic partners involved in the process have
identified these issues and seemwilling to rigorously address
them. Thus, it is to be expected that the number of imaging
biomarkers markers deployed for clinical drug evaluation
will substantially increase during the next decade.
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